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The aim of this study was to evaluate the predictive value of intratumoural microvessel density in breast cancer. We studied
immunohistochemically primary tumours of 104 patients with metastasised breast cancer who took part in a randomised
multicentre trial comparing docetaxel to sequential methotrexate and 5-ﬂuorouracil. Vessels were highlighted with factor VIII
staining and counted microscopically. Microvessel density was compared with clinical response to chemotherapy and patient
survival. The microvessel density of the primary tumour was not signiﬁcantly associated with patient’s response to
chemotherapy, time to progression or overall survival in the whole patient population or in the docetaxel or methotrexate
and 5-ﬂuorouracil groups. However, disease-free survival was longer in patients with low microvessel density (P=0.01). These
ﬁndings suggest that microvessel density of the primary tumour cannot be used as a predictive marker for chemotherapy
response in advanced breast cancer.
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Currently most breast cancer patients suffering from metastatic
disease receive chemotherapy and/or hormone therapy. Curative
treatment is not yet available for metastatic breast cancer and its
management is palliative in almost all cases. Chemotherapy is
frequently toxic and only half of the patients with metastatic
disease usually respond to the treatment. There is a need for
predictive markers for chemoresistant tumours in order to avoid
unnecessary side effects of chemotherapy.
Hormonal receptor status and tumour cell proliferation have
been evaluated as potential predictive factors for chemotherapy
(Corle et al, 1984; Willsher et al, 1998; Zambetti et al, 1999), but
these tumour properties have so far shown little clinical utility.
Recently many proteins including c-erbB-2, p53 and the bcl-2
family have been investigated as predictors for chemosensitivity
(Jacquemier et al, 1994; Muss et al, 1994; Sjo ¨stro ¨m et al, 2000;
Sjo ¨stro ¨m, 2002a,b). However, none of these markers have shown
clinical utility in predicting response for chemotherapy in advanced
breast cancer.
Immunohistochemically measured microvessel density (MVD)
has been applied to quantitate the angiogenesis in breast cancer.
Results from most studies suggest that tumour microvessel density
is associated with lymph node metastasis and worse outcome
(Weidner et al, 1991; Bosari et al, 1992; Gasparini et al, 1994;
Toi et al, 1995; Jacquemier et al, 1998; Hansen et al, 2000)
although in some studies no association was seen (Van Hoef et
al, 1993; Axelsson et al, 1995; Tynninen et al, 1999; Vincent-Salo-
mon et al, 2001). It has also been suggested that MVD may be
associated to endocrine treatment response in breast cancer
(Gasparini et al, 1996).
In this study we investigated whether intratumoural microvessel
density is associated with response to chemotherapy in patients
with metastatic breast cancer. Earlier reports on MVD as a predic-
tive marker for chemotherapy response in advanced breast cancer
have not been published.
MATERIALS AND METHODS
The patient population of the present study was a subgroup of 283
patients participating in a multicentre randomised trial comparing
docetaxel with sequential methotrexate and 5-ﬂuorouracil (MF) in
advanced breast cancer (Sjo ¨stro ¨m et al, 1999). To enter the rando-
mised study, patients were required to have histologically proven
primary breast cancer that had progressed during or after ﬁrst line
anthracycline therapy for advanced disease or relapsed during or
within 12 months after discontinuation of adjuvant anthracycline
therapy. Ethical committees of all participating centres approved
the study. Parafﬁn blocks were available for 134 patients. There
was enough tumour tissue left in the blocks of 109 patients. Five
patients were excluded because of excessive background staining
with factor VIII antibody leaving 104 patients for ﬁnal analysis
(Table 1).
Formalin ﬁxed tissue samples were embedded in parafﬁn. For
immunohistochemistry 5 mm thick sections were cut on coated
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ous peroxidase was blocked. After rinsing the slides were incubated
overnight at room temperature with diluted (1:10000) polyclonal
antibody against factor VIII related antigen (von Willebrand
Factor, DAKO, Glostrup, Denmark) to stain capillary endothelium.
Immunoperoxidase stainings were performed using a commercial
avidin-biotin detection kit (Vectastain
1 Elite ABC Kit, Vector
Laboratories, Burlingame, CA, USA) following the manufacturer’s
instructions. Bound peroxidase was visualised with 3-amino-9-
ethylcarbazole. Finally the sections were counterstained in Mayer’s
haematoxylin.
Tumour microvessel density was determined from areas of high-
est vascularisation within invasive carcinoma. Microscopic slides
were screened at low magniﬁcation (620, 640) to identify the
most vascularised areas. Vessels were counted from the three most
vascularised areas by one investigator (O Tynninen) at a magniﬁ-
cation of 6200 (microscopic ﬁeld area 0.785 mm
2). An average
of three counts reported in vessels per mm
2 was used as the micro-
vessel density of the tumour. The criteria introduced by Weidner et
al (1991) were used to identify microvessels.
Response evaluation was performed according to the WHO
recommendations (Miller et al, 1981). For statistical analysis clini-
cal response was divided into two categories: response (complete
and partial response) and non-response (stable disease and
progression). Differences in treatment response were evaluated with
the w
2 test in the whole patient population, and in the docetaxel
and MF treated groups separately.
Disease free interval (DFI) was measured from the date of the
primary diagnosis until the ﬁrst recurrence of cancer, time to
progression (TTP) from the date of randomisation till disease
progression and overall survival (OS) from the date of randomi-
sation till death. Kaplan–Meier plots were calculated for overall
survival, disease free survival and time to progression. Differences
in survival were tested with Cox logistic regression analysis with
microvessel density as a continuous variable. Spearman correla-
tion coefﬁcients were calculated for MVD and several other
previously assessed tumour related biological factors based on
the same patient material and described elsewhere (Sjo ¨stro ¨m et
al, 2000; Sjo ¨stro ¨m, 2002a,b). These factors included histological
grade, MIB-1, expression of oestrogen receptor (ER), tumour
suppressor protein p53, p21, mdm-2, the apoptosis related
proteins bcl-2, bax, bcl-xL, bag-1, fas, fasL and the oncoprotein
c-erbB-2. P values less than 0.01 for the correlation coefﬁcients
were considered signiﬁcant. In the correlative analyses the signif-
icance level was set lower than the usual 0.05 because of the
multiple comparisons.
RESULTS
The median microvessel density of the tumours was 95.1 vessels
per mm
2 (range 32.3–247.9, 25th and 75th percentile 74.7 and
132.4, respectively. MVD was not signiﬁcantly associated with
response to chemotherapy when tested in the whole patient popu-
lation (P=0.88) nor in separate groups of docetaxel (P=0.13) or
MF (P=0.24) treated patients. However, low microvessel density
showed a trend towards better response rate in the docetaxel arm
(RR 68% vs 40%, Table 2). Overall survival or time to tumour
progression were not associated with MVD in univariate analysis
neither in the whole patient population (P=0.75) nor in docetaxel
(P=0.64) or MF (P=0.88) groups. However, disease free interval
from primary diagnosis to the appearance of ﬁrst metastases was
shorter in patients with tumour MVD above median (P=0.01,
Figure 1).
We also assessed the correlation between MVD and other
tumour biological factors previously studied in the same popula-
tion (Table 3). MVD was inversely correlated with MIB-1
proliferation index (P=0.007). Tumour grade did not correlate with
MVD. Expression of fas ligand (fasL) was positively correlated with
MVD (P=0.002) but no correlation was found with any other
biological factor investigated (Table 3).
DISCUSSION
We studied intratumoural microvessel density in 104 patients with
advanced breast cancer to evaluate its predictive value for
chemotherapy. We could not demonstrate any difference in
response to chemotherapy, overall survival or time to progression
between the patient groups according to vascular density either
in the whole patient material or in the docetaxel arm. However,
in the MF arm there was a trend towards better chemotherapy
response in the low microvessel density group but the difference
was not statistically signiﬁcant. High MVD was associated with
short disease free interval which is in line with several previous
studies (Weidner et al, 1992; Toi et al, 1993; Hansen et al, 2000).
Preclinical studies suggest that chemoresistance might be asso-
ciated with tumour vascularity (Gasparini et al, 1996). Instead of
facilitating the access of chemotherapeutic agents into the tumour
neovascularisation has been proposed to inhibit penetration of
cytotoxic drugs into tumour tissue due to increased interstitial
pressure (Folkman, 1995). Consequently, one would expect that
response to chemotherapy in more vascularised tumours would
be weaker compared to those with low MVD which is in accor-
dance with our ﬁndings in the docetaxel group.
Against our expectations response to docetaxel was not related
to microvessel density. Previous reports suggest that taxanes
including docetaxel used in this study also harbour an anti-angio-
genic effect themselves (Belotti et al, 1996; Sweeney et al, 2001).
However, in the present study, the methodology to test the predic-
tive value of MVD for response to taxanes was not optimal. MVD
and other parameters were counted in the primary tumour and the
measured outcome was clinical response after disease recurrence
which may be a source of error because the biological properties
of metastases may differ from the primary tumour.
To the best of our knowledge there are no previous report on
the predictive utility of MVD for chemotherapy in advanced breast
cancer. Two studies have investigated microvessel density in breast
cancer patients receiving either adjuvant or neoadjuvant
chemotherapy. In one study Protopapa et al (1993) demonstrated
that the patients who survived longer after mastectomy and
chemotherapy had higher MVD. In the other study Paulsen et al
(1997) did not ﬁnd any difference in the outcome according to
MVD in patients treated with neoadjuvant chemotherapy.
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Table 1 Characteristics of the primary tumour at the time of diagnosis
and treatment related characteristics of the 104 investigated patients
No. of
Factor Subgroup patients (%) Median (range)
Histology Ductal 96 (92)
Lobular 8 (8)
ER Positive 51 (49)
Negative 45 (43)
Unknown 8 (8)
DFI 104 1.7 years (0–23)
Treatment Docetaxel 53 (51)
MF 51 (49)
Response to treatment
Docetaxel CR+PR 26 (52)
MF CR+PR 14 (27)
TTP 104 4.1 months (0.6–29)
OS 104 9.2 months (0.6–36)
ER=oestrogen receptor; DFI=disease free survival; CR=complete response;
PR=partial response; TTP=time to progression; OS=overall survival.
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other tumour biological factors (histological grade, MIB-1, ER, p53,
p21, mdm-2, bcl-2, bax, bcl-xL, bag-1, fas, fasL and c-erbB-2). Only
two signiﬁcant correlations were seen. We noted an inverse correla-
tion between MVD and MIB-1 proliferation which is in line with the
recent ﬁndings by another group (Medri et al, 2000). However, most
studies have not found signiﬁcant association between MVD and
MIB-1 proliferation index (Weidner et al, 1992; Vartanian and
Weidner, 1994; Jacquemier et al, 1998; Tynninen et al, 1999).
The positive correlation between vascular density and fas ligand
expression was particularly interesting. The fas receptor belongs to
the family of tumour necrosis factor related death receptors and
fasL is its corresponding ligand. Binding of a death ligand to its
receptor activates one major apoptotic pathway. Results from some
preclinical studies suggest that classic anticancer drugs may need
fas and fasL to induce apoptosis. Interestingly, stimulation of fas
receptor by agonistic anti-fas monoclonal antibodies also promotes
angiogenesis in murine model (Biancone et al, 1997). Thus, fas
receptor stimulation by fasL might induce angiogenesis in breast
cancer as well. These ﬁndings may explain why fasL expression
was correlated with angiogenesis in our material. Further studies
are required to conﬁrm the possible role of apoptotic fas/fasL
system in tumour neovascularisation.
In conclusion the results of this study suggest that microvessel
density of primary tumour is not useful in predicting response
to taxane or 5-ﬂuorouracil based chemotherapy in advanced breast
cancer.
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Figure 1 Kaplan–Meier plot showing disease free interval in 104 breast
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